SPEECH-PROCESSING
4.2.2020 11:03:11 CET | Business Wire | Press release
Speech Processing Solutions , the market leader in professional dictation, has announced that its portfolio of speech-to-text software is now available on a subscription basis. Flexible low monthly subscription costs make it easier for organizations to take advantage of the full range of available speech-to-text services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005443/en/
Philips dictation and transcription software streamlines the document creation process and facilitates communication between authors and transcriptionists. It enables everything from automated file routing to an on-demand “pay as you go” transcription service or automatic speech recognition to help business of all sizes fulfill their unique needs.
“Philips speech-to-text software helps businesses reach their goals by helping them become even more efficient, profitable and successful, whether this means scoring new top clients or simply having more time for their current customers,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.
High-tech innovation to boost voice-based productivity
Philips software is designed around the customers’ needs and has been developed in close collaboration with end-users. Philips understands that different businesses have personalized needs and preferences. Regardless of whether they are small, mid-sized or large, prefer an on-premise or cloud solution, or run an environment with a few laptops or a complex multi-branch setup across several countries, various voice-to-text options are available to help organizations address every business requirement.
The subscription-based speech-to-text portfolio includes Philips SpeechExec Pro, Philips SpeechExec Enterprise and SpeechLive. The new Philips SpeechExec Pro version 11.5 features a refreshed, more user-friendly interface and supports the latest operating systems available in the market. SpeechLive, Philips’s web dictation and transcription solution, now boasts a brand-new speech-to-text service that offers users speech recognition in real-time. This not only saves users time while working on documents, but also money and hassle as no additional speech recognition software needs to be purchased and installed. SpeechLive offers constant file access to increase mobility, helping professionals to work from anywhere and at any time. Now available as a one- or two-year subscription package, Philips SpeechExec Enterprise, which is ideal for large, multi-branch businesses, supports workflow processes that require central administration and virtual environments.
“Quick and effective communication is key in today’s complex business world. Working in a fast-paced environment requires effortless collaboration and efficient processes no matter what the size of your organization. Our Philips workflow software solutions allow you to do just that, while new subscription models enable businesses to be more agile and cost-efficient than ever before,” explains Dr. Brauner.
All Philips software is optimized to support the industry-leading range of Philips dictation devices including the SpeechMike series, the hands-free dictation headset SpeechOne and the Android-based SpeechAir.
For a free trial of Philips workflow solutions, go to: www.philips.com/speech
About Speech Processing Solutions
Speech Processing Solutions (SPS) is an international technology company and a global leader in dictation solutions. More than four million users worldwide work with speech-to-text solutions developed by SPS and sold under the Philips brand. These solutions include web-based and desktop workflow software as well as dictation devices. These smart solutions save users’ time and allow them to focus on their core tasks, making their business more efficient, customer-centric and profitable.
Headquartered in Vienna, Austria, SPS has regional offices in the United States, Canada, Australia, the United Kingdom, Germany, France, Belgium and Austria, as well as a network of more than 1000 distribution and implementation partners worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005443/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
